Daiichi Sankyo Suspends Japan Nimotuzumab NSCLC Trials
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has decided to suspend Phase III trials with the anti-EGFR antibody nimotuzumab for the treatment of non-small cell lung cancer after four reported patient deaths, the company announced on April 25.